The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.

The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.

Healthy

The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.
Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments.

Omega-3 + vitamin K2 (monoacylglycerol form)

Omega-3 + vitamin K2 (ethyl ester)

Centre de Recherche sur le Vieillissement

Pharmacokinetics of Omega-3 Monoglycerides

Comparison of Pharmacokinetics of Omega-3 Fatty Acid Supplements in Monoacylglycerol or Ethyl Ester in Humans: a Randomized Controlled Trial.

Define by the area under the curve between 0-5h

Define by the area under the curve between 0-24h

Define by the highest concentration achieved by the participants

Mélanie Plourde

Associate professor, Department of medicine, Geriatric service

Université de Sherbrooke

Double-blind controlled-randomized pharmacokinetic (PK) pilot study with crossover design (10 men and 10 women), with a minimum of 6 days between treatments

Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.

Metabolic Syndrome

Hypertriglyceridemia

omega-3 acid ethyl esters

extended release niacin

placebo

omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm

ethyl ester/ניוון ביולוגיה

Pharmacokinetics of Omega-3 Monoglycerides

Niacin, N-3 Fatty Acids and Insulin Resistance

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע